C4 therapeutics to host webcast to present new dose escalation data from cft7455 phase 1 study in relapsed/refractory multiple myeloma

Watertown, mass., nov. 28, 2023 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that it will host a webcast on tuesday, december 12, 2023 at 4:30 pm et to present new phase 1 dose escalation data for relapsed refractory multiple myeloma from the ongoing phase 1/2 clinical trial of cft7455, a monodac™ degrader of ikzf1/3, for the potential treatment of relapsed/refractory multiple myeloma and relapsed/refractory non-hodgkin's lymphoma.
CCCC Ratings Summary
CCCC Quant Ranking